Omeros (OMER) Misses Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Omeros (OMER) Misses Q1 EPS by 11c
May 10, 2016 7:20 AM EDT
-- Conference Call Today at 9:00 a.m. ET --
SEATTLE--(BUSINESS WIRE)--
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed
to discovering, developing and commercializing both small-molecule and
protein therapeutics for large-market as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system, today announced recent highlights and developments as
well as financial results for the first quarter of 2016, which include:
1Q 2016 revenues were $7.4 million, an 11% increase over 4Q 2015.
Net loss in 1Q was $20.5 million, or $0.54 per share, which included
$4.7 million ($0.12 per share) of non-cash...
More
May 10, 2016 7:05 AM EDT
SEATTLE--(BUSINESS WIRE)--
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed
to discovering, developing and commercializing both small-molecule and
protein therapeutics for large-market as well as orphan indications
targeting inflammation, coagulopathies and disorders of the central
nervous system, today announced the hiring of Leonard Blum as chief
business and commercial officer. Mr. Blum is leading the companys
sales, marketing, commercial strategy and planning, and business
development, including for OMIDRIA® (phenylephrine and
ketorolac injection) 1% / 0.3% and the companys growing pipeline of
development-stage programs.
Mr. Blum brings over 28 years of executive and management experience in... More
